In July 2020, the U.S. FDA has Approved an Adalimumab Biosimilar Manufactured by Mylan N.V. and Indicated for Treatment of Rheumatoid Arthritis, Juvenile Arthritis Among other Inflammatory Diseases

As per the publication of August 2020, entitled "Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry", this has been demonstrated that out of the total subjects considered under study 64.1% relied on adalimumab therapy for 1 year and 10.2% relied on more than 12 years. The patients reported had the mean age of 53.9 years or more than that.        

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-adalimumab-market

Global adalimumab market is expected to reach USD 28,508.07 million by 2027 from USD 19,905.00 million in 2019, growing with the CAGR of 4.8% in the forecast period of 2020 to 2027. The demand for adalimumab has been increased in both developed well as in developing countries and the reason behind this is the rise in the prevalence of inflammatory autoimmune diseases. The adalimumab market is growing due to the growing geriatric population and an increasing number of contract research organizations. The market will grow in the forecasted period due to the presence of product pipeline, strategic initiatives by market players, and increasing healthcare expenditure among others.            

Increasing prevalence of rheumatoid arthritis across the world will drive the market's growth rate

The prevalence of rheumatoid arthritis is increasing worldwide and this has been reported that globally, the annual incidence of RA is nearly 3 cases per 10,000 populations. Rheumatoid arthritis leads to development of inflammatory symptoms which can be treated by several drug therapies involving biological therapies, among others. One of the most innovative biological therapy discovered for treatment of rheumatoid arthritis includes adalimumab, a monoclonal antibody which targets the immune cells ad slows down the recruitment of immune cells that leads to decrease the inflammation at target site. Rheumatoid arthritis is one of the chronic diseases and has become the worldwide healthcare concern. The changes in lifestyle pattern, physical inactivity and increasing geriatric population are some factors responsible for increasing the prevalence of rheumatoid arthritis.

Report Scope and Market Segmentation

Segment Analysis:

Global adalimumab market is categorized into eight notable segments which are indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel.

• On the basis of indication, global adalimumab market is segmented into rheumatoid arthritis, ankylosing spondylitis, psoriatric arthritis, chronic plaque psoriasis, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate, others. In 2020, rheumatoid arthritis segment is expected to dominate the market with 28.20% market share because it is a very common autoimmune systemic inflammatory disease affecting approximately 1% of the worldwide population. Moreover, worldwide, the annual incidence of RA is approximately 3 cases per 10,000 populations.
• On the basis of type, global adalimumab market is segmented into biologics, and biosimilars. Biosimilars segment is further sub-segmented into adalimumab-ATTOto, adalimumab-BWWD, adalimumab-ADBM, adalimumab-FKJP, adalimumab-ADAZ, adalimumab-AFZB, and others. In 2020, biologics segment is expected to dominate the market with 94.99% market share because less number of biosimilars present worldwide. Moreover, AbbVie have still patent right on the product for the U.S. market.
• On the basis of dosage strength, global adalimumab market is segmented into 40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.4mlg, 10mg/0.1mlg, others. In 2020, 40mg/0.4mlg segment is expected to dominate the market with 36.42% market share because majority of population or patients suffering from RA or other inflammatory diseases are using 40mg dose and it's the most useable dose for the treatment.
• On the basis of drug type, global adalimumab market is segmented into branded, generics. In 2020, branded segment is expected to dominate the market with 94.99%market share because less number of biosimilars present worldwide. Moreover, AbbVie Inc. have still patent right on the product for the U.S. market.
• On the basis of route of administration, global adalimumab market is segmented into parenteral, oral. Parenteral segment is further sub- segment into subcutaneous, intramuscular. In 2020, parenteral segment is expected to dominate the market with 100.00% market share because adalimumab is a human monoclonal antibody can only be given through SC route for the long term effect.
• On the basis of population type, global adalimumab market is segmented into adults, children. In 2020, adults segment is expected to dominate the market with 68.93% market share because majority of population suffering from inflammatory diseases are adult population and majority of clinical data supporting the adult population data.
• On the basis of end user, global adalimumab market is segmented into hospitals, specialty clinics, home healthcare, others. In 2020, hospitals segment is expected to dominate the market with 46.52% market share because presence of skilled professionals and adalimumab is a costly injection which comes under the insurance panel.

The hospitals segment will dominate the end user segment of the adalimumab market

The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, global adalimumab market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, direct tenders, others. In 2020, hospital pharmacies segment is expected to dominate the market with 51.99% market share because of presence of experienced professional and adalimumab is only prescribed by the doctors, so one can only by from the hospital pharmacies at a reasonable price.

The hospital pharmacies segment will dominate the distribution channel segment of the adalimumab market

The hospital pharmacies segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Biogen (U.S.), Fresenius Kabi AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Amgen Inc. (U.S.),  AbbVie Inc. (U.S.), Abbott (U.S.), CELLTRION INC. (South Korea), Samsung Bioepis (South Korea), Coherus BioSciences (U.S.), Innovent Biologics, Inc. (China), Hetero Biopharma Ltd. (India), Reliance Life Sciences (India).

Market Development

• In November 2019, Samsung Bioepis (A Subsidiary of Samsung Biologics) went under a commercialization agreement with Biogen for different types of biosimilar products the company is manufacturing. As per the agreement the company has earned lucrative sales in European region which has boosted the company's revenue.
• In April 2018, Biogen signed a settlement agreement with AbbVie Inc. with an aim to accelerate the commercialization of IMRALDI, which is the reference product of HUMIRA. This settlement agreement allowed the company to fulfill unmet patient needs at an efficient healthcare cost.
• In October 2018, Amgen Europe GmbH (A Subsidiary of Amgen Inc.) launched AMGEVITA, a biosimilar to adalimumab in European region. This product has been proved efficacious for treatment of several kinds of inflammatory diseases. This initiative boosted the company's product portfolio and allowed the company to expand its revenue in the worldwide adalimumab market.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in adalimumab market during the forecast period 2020 - 2027

North America dominates the adalimumab market because of the growing geriatric population and surging prevalence of rheumatoid arthritis in this region. Additionally the rising healthcare expenditure will further propel the market's growth rate in this region.

Asia-Pacific is estimated to be the fastest-growing region in adalimumab market the forecast period 2020 - 2027

Asia-Pacific are expected to grow during the forecast period due to surging focus for the development of generic and biosimilar products and the increasing number of geriatric population in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.    

COVID-19 Impact

The cause of the pneumonia cases was determined to be COVID-19, a brand-new coronavirus. The rapid global spread of this virus resulted in a significant number of fatalities. The World Health Organization (WHO) declared COVID-19 a global pandemic in March 2020 and advised strict action to stop the disease's spread. Since then, the pandemic has slowed down healthcare industry growth and hampered the supply chain. To stop the spread of COVID-19, governments in several countries have enacted nationwide lockdowns. Similar issues prevented healthcare firms around the world from carrying out their supply chain operations. The slowness of the supply chain restricted the market for adalimumab.

For more detailed information about the adalimumab market, visit: https://www.databridgemarketresearch.com/reports/global-adalimumab-market